Although some companies, including Inovio, have released interim trial data, it isn't enough to draw conclusions. Through computer sequencing, Inovio reorganizes tiny circles of DNA -- DNA plasmids -- to spur an immune response.
Inovio is a strong buy because of how low the bar is for approval of coronavirus vaccines. French GDP beat expectations inflation data is awaited from the old continent. Gold is on track to print double-digit monthly gains. The rally could be attributed to the dollar sell-off and negative yields on the US Treasury inflation-protected securities (TIPS). But Inovio didn't provide further details regarding neutralizing antibodies.
Please read our privacy policy and legal disclaimer.EUR/USD is trading near 1.19, the highest since June 2018 as weak data, stimulus uncertainty, coronavirus, and other factors weigh on the dollar.
Inovio Pharmaceuticals (NASDAQ:INO) is one of the biotech companies everyone is talking about these days. This, according to …
Bulls will have a bumpy road unless refreshing the monthly top.Shares have been surging in recent days, including a leap of 30.92% on Thursday. NASDAQ: INO shares are benefiting from the coronavirus contract the firm signed with the DOD. Still, data often can offer us a few clues about whether we should be somewhat optimistic about a program or not.Inovio's vaccine candidate is based on the company's DNA medicines technology. Inovio said it is planning to begin a mid-to-late stage study in summer to measure the vaccine’s efficacy.
INOVIO is currently preparing to initiate a Phase 2 vaccine trial for INO-4700 in the Middle … After this near seven-fold rise, will it correct or continue higher?WTI prints two-day losing streak while keeping downside break of monthly support line and 21-day SMA. Agreement will facilitate clinical trial translations in China Inovio Pharmaceuticals, Inc. (NASDAQ: INO) today announced that it is collaborating with Beijing Advaccine Biotechnology Co. to advance the development in China of INO-4800, Inovio's vaccine against the recently emerged strain of coronavirus (2019-nCoV) that has killed numerous people and infected thousands more in China to date.
These two recruits could boost the company forward. The US dollar has been extending its sell-off, falling to multi-month or multi-year lows against currencies. Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today announced the Coalition for Epidemic Preparedness Innovations (CEPI) has awarded Inovio a grant of up to $9 million to develop a vaccine against the recently emerged strain of coronavirus (2019-nCoV) that has killed numerous people and infected hundreds more in China to date. Inovio’s COVID-19 vaccine, INO-4800, was developed in just 3 hours once the COVID-19 sequence was deposited in data banks for public access.